EUVIMEDEUVIMED entdecken
Crossref

Supramolecular self-assemblies of H6/doxorubicin reverse P-gp-mediated multidrug resistance in breast cancer

Qingquan Sun, Yan Wei, Baoyuan Sun, Qian Jiang, Daquan Chen, Yi Bi, Yongchao Chu

European Journal of Pharmaceutics and Biopharmaceutics · 2026-08 · 225 · 115102

DOI: 10.1016/j.ejpb.2026.115102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmaceutics and Biopharmaceutics, 2026-08. Verfasst von Qingquan Sun und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation…. Hauptthemen laut MEDLINE: Doxorubicin, Drug Resistance, Neoplasm, Drug Resistance, Multiple, Breast Neoplasms. Die Arbeit nennt 24 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Yantai University, Taishan Scholar Project of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor multidrug resistance (MDR) remains a major cause of chemotherapy failure. Inhibiting the P-glycoprotein (P-gp)-mediated excessive efflux of chemotherapeutic drugs represent an effective strategy to overcome MDR. Conventional P-gp inhibitors are limited in clinical use due to systemic toxicity and risks of normal tissue dysfunction. In this study, we constructed a self-assembled system based on H6, the α-hederagenin derivative with potent MDR reversal activity, and the chemotherapeutic agent doxorubicin (DOX). Guided by the CREKA peptide, this system specifically targets fibronectin in tumor tissues, thereby enhancing drug accumulation at the lesion site. The combination therapy of H6 and DOX exhibited a combination index (CI) of 0.16 (CI < 1), indicating strong synergistic effects. Both in vitro and in vivo experiments demonstrated that H6 interferes with ATP production and effectively inhibits P-gp efflux function. In a breast cancer MDR model, this strategy achieved a tumor inhibition rate of 81.7%, offering a promising approach to combat tumor MDR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinDrug Resistance, NeoplasmDrug Resistance, MultipleBreast NeoplasmsATP Binding Cassette Transporter, Subfamily B, Member 1AnimalsFemaleHumansMiceCell Line, TumorXenograft Model Antitumor AssaysAntibiotics, AntineoplasticAntineoplastic Agents

Stichwörter der Autor:innen

Breast cancerCREKA peptideDoxorubicinMultidrug resistanceP-glycoproteinSelf-assembly

Substanzen

DoxorubicinATP Binding Cassette Transporter, Subfamily B, Member 1Antibiotics, AntineoplasticAntineoplastic Agents

Autor:innen und Institutionen

  • School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universi…

Förderung

  • National Natural Science Foundation of China
  • Yantai University
  • Taishan Scholar Project of Shandong Province
  • Natural Science Foundation of Shandong Province

Zitieren

APA

Sun, Q., Wei, Y., Sun, B., Jiang, Q., Chen, D., Bi, Y., & Chu, Y. (2026). Supramolecular self-assemblies of H6/doxorubicin reverse P-gp-mediated multidrug resistance in breast cancer. European Journal of Pharmaceutics and Biopharmaceutics, 225, 115102. https://doi.org/10.1016/j.ejpb.2026.115102

Vancouver

Sun Q, Wei Y, Sun B, Jiang Q, Chen D, Bi Y, et al. Supramolecular self-assemblies of H6/doxorubicin reverse P-gp-mediated multidrug resistance in breast cancer. European Journal of Pharmaceutics and Biopharmaceutics. 2026;225:115102. doi:10.1016/j.ejpb.2026.115102

BibTeX
@article{Sun2026,
  author = {Sun, Qingquan and Wei, Yan and Sun, Baoyuan and Jiang, Qian and Chen, Daquan and Bi, Yi and Chu, Yongchao},
  title = {Supramolecular self-assemblies of H6/doxorubicin reverse P-gp-mediated multidrug resistance in breast cancer},
  journal = {European Journal of Pharmaceutics and Biopharmaceutics},
  year = {2026},
  volume = {225},
  pages = {115102},
  doi = {10.1016/j.ejpb.2026.115102}
}
Kostenlos starten →